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The Hangzhou Huadong medicine listed in 2000 in Shenzhen stock market, It has 
potential achievement not only in medicine trade——the biggest medicine trade company 
in Zhejiang, but also in medicine industry——Faculty medicine. Medicine is a profession 
which has a high profession threshold, many people can not understand it,investing in 
medicine is too hard for someone, but it has more investing opportunity than before. The 
medicine profession elasticity is minimum, can resist the economic fluctuation so, this 
paper introduces and analyzes Hangzhou Huadong medicine. 
There are six chapters in this paper. 
ChapterⅠintroduces the historical development, the corporate business and the 
product introduction of the company.  
ChapterⅡ  is the Chinese medicine profession analysis. It introduces present 
medicine profession situation, profession characteristic, existence question and so on.  
ChapterⅢ is the financial analysis. It mainly takes 2005-2007 year annual report to 
analyzes and evaluate the company.  
ChapterⅣ  is the SWOT analysis. It analyzes the company from  superiority, 
inferiority, opportunity and challenge.  
ChapterⅤ is the evaluation. It uses DCF,PE,PB,PE to evaluate the company, and 
give a value sector. 
ChapterⅥ is the investment risk analysis. It analyze from the policy change risk, the 
drugs security risk, the profession competition risk and the stock market. 
After researching, it shows that Huadong medicine has the investment opportunity. 
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第 1 章  华东医药股份有限公司简介 
本章将介绍华东医药的组建历程、股东情况，并对其主要业务进行具体分析，
以初步了解华东医药的具体情况，有利于本文后面的分析。 
 1.1  华东医药股份有限公司组建历程 
华东医药股份有限公司前身为杭州医药站股份有限公司，是经浙江省股份制
试点工作协调小组浙股[1992]56号文批准，由杭州医药采购供应站作为主发起人, 
联合杭州民生药厂、浙江新昌制药股份有限公司共同发起，于 1993 年 3 月以定
向募集方式设立的。 
公司设立时注册资本 8000 万元，每股面值 10 元，总股本 800 万股。其中杭
州医药采购供应站以经评估后的经营性净资产 4787 万元作价投入股份公司，行





1996 年 11 月，杭州医药站股份有限公司在对原股本结构进行清理、规范的
基础上进行配股并更名。对法人股个人化和内部职工股社会化等进行清理后，公
司总股本为 7400 万股，以此为基数，公司按 10：8.919 的比例向股东配股。 杭
州华东医药（集团）公司将其持有的杭州中美华东制药有限公司中方 75% 的股
权经评估后折价认购该次配股股份。 
1997 年 1 月 17 日，公司完成工商变更登记， 更名为杭州华东医药股份有
限公司，总股本增至 14000 万股。至此， 本公司从单纯的商业企业一举成为集
医药产品生产和销售网络于一体的、工商紧密结合的医药生产企业。 
1998 年 7 月，杭州华东医药（集团）公司将其持有的本公司 10987 万股国


















1999 年 12 月 30 日再次更名为华东医药股份有限公司，取得浙江省工商行
政管理局核发的注册号为 3300001005765 的《企业法人营业执照》。公司股票于
2000 年 1 月 27 日在深圳证券交易所挂牌交易。 



































Degree papers are in the “Xiamen University Electronic Theses and Dissertations Database”. Full
texts are available in the following ways: 
1. If your library is a CALIS member libraries, please log on http://etd.calis.edu.cn/ and submit
requests online, or consult the interlibrary loan department in your library. 
2. For users of non-CALIS member libraries, please mail to etd@xmu.edu.cn for delivery details.
厦
门
大
学
博
硕
士
论
文
摘
要
库
